<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821507</url>
  </required_header>
  <id_info>
    <org_study_id>COSYMO</org_study_id>
    <nct_id>NCT02821507</nct_id>
  </id_info>
  <brief_title>Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma</brief_title>
  <official_title>A Phase 2, Single Arm, Multi Center Trial Evaluating the Efficacy of the COmbination of Sirolimus and cYclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and chOndrosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient&#xD;
      survival. Current treatment options consist of wide surgical resection, however for patients&#xD;
      with a local recurrence or metastatic disease the outcome is poor. New treatment options&#xD;
      being evaluated and mouse models show in vivo that mammilian target of rapamycin (mTOR)&#xD;
      inhibition can prevent tumour growth. mTOR is an kinase that is present in two complexes and&#xD;
      thereby activates multiple pathways. Aberrant mTOR signalling is known to be involved in&#xD;
      cancer cell survival. Several clinical studies for patients with bone or soft tissue sarcoma&#xD;
      treated with mTOR inhibitors have been conducted and they show promising results. From these&#xD;
      studies the investigators can conclude that the combination of an mTOR inhibitor with&#xD;
      cyclophosphamide shows promising results in chondrosarcoma. With the lack of other treatment&#xD;
      options for unresectable and metastatic chondrosarcoma or myxoid liposarcoma the Eurosarc&#xD;
      consortium (www.eurosarc.eu) decided to treat these patients in a standardised way according&#xD;
      to a common protocol with the combination of sirolimus and cyclophosphamide using the growth&#xD;
      modulation index for evaluation in the current clinical study protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to progression after start of treatment combination treatment of sirolimus and cyclophosphamide</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing pre-treatment tumor material and tumor material taken during treatment using immunohistochemistry to compare activation of the pS6, Bcl-2 and mTor pathway and DNA analysis for taqman analysis to search for hotspot mutations.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Register adverse events to evaluate the patient safety and tolerability of the sirolimus and cyclophosphamide combination in myxoid liposarcoma and chondrosarcoma</measure>
    <time_frame>every 8 weeks until progression (average of 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the response according to response evaluation criteria in solid tumors (RECIST) 1.1</measure>
    <time_frame>every 8 weeks until progression (average of 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Using the growth modulation index (GMI) to evaluate treatment efficiency</measure>
    <time_frame>every 8 weeks until progression (average of 1 year)</time_frame>
    <description>GMI: Time to progression during sirolimus/cyclophosphamide treatment (TTP2) divided by time to progression before start of this treatment TTP1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall survival after start of treatment till death</measure>
    <time_frame>every 8 weeks until progression (average of 1 year)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Conventional Chondrosarcoma</condition>
  <condition>Myxoid Liposarcoma</condition>
  <condition>Mesenchymal Chondrosarcoma</condition>
  <condition>Dedifferentiated Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>sirolimus and cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus and cyclophosphamide</intervention_name>
    <arm_group_label>sirolimus and cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically proven conventional chondrosarcoma&#xD;
&#xD;
          -  Or pathologically proven myxoid liposarcoma with PIK3CA mutation or Phosphatase and&#xD;
             tensin homolog (PTEN) loss&#xD;
&#xD;
          -  Or pathologically proven mesenchymal or dedifferentiated chondrosarcoma&#xD;
&#xD;
          -  Patient is 18 years and up&#xD;
&#xD;
          -  Documented radiographic progression of disease according to RECIST 1.1 criteria in&#xD;
             last 6 months&#xD;
&#xD;
          -  Written signed informed consent&#xD;
&#xD;
          -  Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x&#xD;
             109/L, platelets ≥ 80 x 109/L)&#xD;
&#xD;
          -  Availability of archival tumor material for central review or be able to perform a 3&#xD;
             core fresh biopsy&#xD;
&#xD;
          -  Ability to adhere to the study visits and all protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously treated with an mTOR inhibitor&#xD;
&#xD;
          -  Known to be allergic to cyclophosphamide&#xD;
&#xD;
          -  Life expectancy of less than 3 months&#xD;
&#xD;
          -  No measurable lesions according to RECIST 1.1&#xD;
&#xD;
          -  Eastern cooperative oncology group (ECOG) Performance status &gt;2&#xD;
&#xD;
          -  Major surgery less than 4 weeks prior to start of treatment&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positivity&#xD;
&#xD;
          -  A decreased renal function with calculated glomerular filtration rate (GFR) &lt; 30ml/min&#xD;
&#xD;
          -  Systemic anti-cancer therapy within 28 days prior to the first dose of study drug , or&#xD;
             radiotherapy to a target lesion within 21 days prior to the first dose of study drug&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Other invasive malignancies diagnosed within the last 5 years, except non-melanoma&#xD;
             skin cancer and localised cured prostate and cervical cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Gelderblom, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Val d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIO Clara Campal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico de La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>HansGelderblom</investigator_full_name>
    <investigator_title>Prof A.J. Gelderblom</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
    <mesh_term>Chondrosarcoma, Mesenchymal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

